Compounds > piperonyl butoxide
Page last updated: 2024-11-06

piperonyl butoxide and Liver Diseases, Parasitic

piperonyl butoxide has been researched along with Liver Diseases, Parasitic in 2 studies

Liver Diseases, Parasitic: Liver diseases caused by infections with PARASITES, such as tapeworms (CESTODA) and flukes (TREMATODA).

Research Excerpts

ExcerptRelevanceReference
"Piperonyl butoxide (PB) was the CYP P450 inhibitor used."1.37Piperonyl butoxide enhances triclabendazole action against triclabendazole-resistant Fasciola hepatica. ( Alvarez, LI; Brennan, GP; Devine, C; Fairweather, I; Hoey, E; Lanusse, CE; Trudgett, A, 2011)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Devine, C2
Brennan, GP2
Lanusse, CE2
Alvarez, LI2
Trudgett, A2
Hoey, E2
Fairweather, I2

Other Studies

2 other studies available for piperonyl butoxide and Liver Diseases, Parasitic

ArticleYear
Inhibition of cytochrome P450-mediated metabolism enhances ex vivo susceptibility of Fasciola hepatica to triclabendazole.
    Parasitology, 2010, Volume: 137, Issue:5

    Topics: Animals; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Fasc

2010
Piperonyl butoxide enhances triclabendazole action against triclabendazole-resistant Fasciola hepatica.
    Parasitology, 2011, Volume: 138, Issue:2

    Topics: Animals; Benzimidazoles; Cell Membrane; Cytochrome P-450 Enzyme Inhibitors; Drug Combinations; Drug

2011